Why Mounjaro Can Increase Your Heart Rate — and What to Do About It

Step 1, Understanding the mechanism behind the heart-rate rise

Tirzepatide is a dual GIP and GLP-1 receptor agonist. Both receptor types are found not just in the gut and pancreas but in cardiac and autonomic tissue. When GLP-1 receptors are activated, they have a mild sympathomimetic effect, that is, they slightly increase sympathetic nervous system tone, which in turn raises the heart's resting rate. The GIP component adds a secondary layer of autonomic signalling. The net result is a small but measurable uptick in beats per minute that shows up reliably in trial data. It is structurally similar to the heart-rate effect seen with other GLP-1 receptor agonists and is considered a class effect rather than something unique to tirzepatide. The NHS medicines page for tirzepatide lists a faster heartbeat among the side effects patients should be aware of, placing it in the category of effects to monitor rather than to fear.

A question our prescribers hear most weeks: "My heart is racing, have I taken too much?" Usually the answer is no. A few extra beats at rest is not the same as a racing heart, and the distinction matters when deciding what action to take.

Step 2, When the rise typically happens and how long it lasts

The timing follows the dose schedule closely. Heart rate tends to climb in the first few days after starting at 2.5 mg and again after each upward titration step. The starter dose exists primarily to let the body acclimatise, not just to gastrointestinal effects but to cardiovascular ones too. For most people the rise is transient: it peaks in the first week at a new dose and then drifts back toward baseline, even as the dose stays the same. The body's autonomic system recalibrates. This pattern is one reason the dose-escalation schedule is deliberately slow, four-week intervals give physiology time to catch up. If you are tracking your heart rate with a wearable device, expect small fluctuations and avoid over-interpreting a single high reading after a new pen. What matters is the average over several days, measured at rest, ideally at the same time each morning.

People who were already on a higher resting heart rate before starting treatment may notice the effect more, and those restarting Mounjaro after a break should be aware that returning at 5 mg rather than the lowest dose can make this effect more noticeable. The prescriber's baseline assessment is partly there to capture exactly this.

Step 3, What a larger or persistent rise might mean, and when to seek help

A persistent increase well above the 2–4 bpm range, or palpitations accompanied by chest tightness, breathlessness, or light-headedness, warrants prompt medical advice. These symptoms are not typical of the expected pharmacological effect and could reflect something unrelated to tirzepatide that needs investigation. Similarly, if your heart rate has been elevated for more than two to three weeks at a stable dose without settling, that is worth raising with your prescriber rather than waiting for the next scheduled review. The BNF entry for tirzepatide notes tachycardia as a known adverse effect and flags the importance of cardiovascular monitoring in individual patients. Understanding what counts as a Mounjaro-related heart-rate increase versus something else is a practical starting point before calling anyone. Do not stop the medicine abruptly without speaking to your prescriber first, that decision depends on the full clinical picture and how your treatment is going. You can read more about how dose changes relate to these effects on the dose and weight-loss outcomes page.

What this means in practice: monitoring and your prescriber's role

Routine self-monitoring is straightforward. Check your resting heart rate in the morning before getting out of bed, ideally with a validated device, and note any readings that feel unusual alongside other symptoms like dizziness or palpitations. Share that log at your next clinical review. Most people find the effect barely noticeable; some feel a mild fluttering in the first week after a new dose; a small number need the titration pace adjusted or a clinical conversation about whether to stay at the current dose rather than going higher. That last scenario is precisely why the decision to increase the dose belongs with a prescriber rather than being automatic. If you are considering treatment and want to understand how our clinical team approaches this, the clinical team profile gives a sense of the oversight involved. For a broader picture of tirzepatide's side-effect profile and how the treatment works, the Mounjaro overview covers the full landscape. When you are ready to explore whether tirzepatide could be right for you, check your eligibility through a free consultation, a prescriber, not an algorithm, reads every submission the same day.